Adalimumab

The FDA has approved the seventh biosimilar to adalimumab, adalimumab-aqvh, for all eligible indications of the biologic product, the latest in an increasingly crowded biosimilar logjam set to release in 2023.

Among patients with inflammatory bowel disease who received at least two biologic therapies, discontinuation of treatment appeared to vary based on initial treatment choice, according to data presented at the ACG Annual Scientific Meeting.

The FDA recently approved Cyltezo as the first interchangeable biosimilar for certain inflammatory diseases, allowing prescribers to substitute it for Humira without a prescription change. It was the top story in rheumatology last week.

LAS VEGAS – Matching-adjusted indirect comparisons found a positive benefit-risk profile for ozanimod vs. adalimumab and a comparable profile for ozanimod vs. vedolizumab.

Patients with rheumatoid arthritis who achieved greater response with tofacitinib do so regardless of whether methotrexate was added to therapy or not, according to data published in Arthritis Research & Therapy.

Adalimumab biosimilar BI 695501 demonstrated similar safety and efficacy compared with adalimumab reference product among patients with Crohn’s disease, according to research published in the Lancet Gastroenterology and Hepatology.

Adalimumab was an efficacious and safe treatment option for pediatric patients with moderate to severe ulcerative colitis, according to findings published in Lancet Gastroenteroly and Hepatology.

Methotrexate increases the probability of remission with adalimumab or infliximab by 50% in patients with psoriatic arthritis, versus TNF-inhibitor monotherapy, according to data published in the Annals of the Rheumatic Diseases.

Amid a lawsuit battle concerning a Humira biosimilar product between AbbVie and Alvotech, experts predict that the market will explode as greater competition begins to erode Humira’s profits.

On May 11, Icelandic-based drug developer Alvotech filed a lawsuit against AbbVie seeking to undo what it alleges is a “minefield” of “invalid” patents surrounding what is arguably the pharma giant’s most prized possession: Humira.